Understanding how the immune environment affects pancreatic cancer treatment resistance
The Tumor Immune Microenvironment in Pancreatic Cancer Chemoresistance
This study is looking at how certain immune cells in pancreatic cancer patients might make it harder for chemotherapy to work, and by analyzing samples from patients, researchers hope to find ways to better understand and overcome this resistance to treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11097172 on NIH RePORTER |
What this research studies
This research investigates the role of myeloid cells in the immune microenvironment of pancreatic cancer, particularly how they contribute to resistance against chemotherapy. By collecting fresh biospecimens from patients during diagnostic and treatment procedures, the study aims to create a detailed dataset of single-cell sequenced tumors. This approach will help identify the mechanisms behind chemotherapy resistance and how the immune system is altered by treatment. The ultimate goal is to improve understanding of tumor aggressiveness and resistance to therapy in pancreatic cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are undergoing treatment or diagnostic procedures.
Not a fit: Patients with pancreatic cancer who are not receiving treatment or are not eligible for biopsy or surgical resection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for overcoming chemotherapy resistance in pancreatic cancer, potentially improving patient survival rates.
How similar studies have performed: While the specific approach of this research is novel, previous studies have shown that understanding the tumor microenvironment can lead to breakthroughs in cancer treatment.
Where this research is happening
Ann Arbor, United States
- Veterans Health Administration — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Carpenter, Eileen S — Veterans Health Administration
- Study coordinator: Carpenter, Eileen S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.